Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Best practices for managing cough in PAH patients receiving inhaled therapies

Wednesday, December 11, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses best practices for managing cough in patients with pulmonary arterial hypertension (PAH) who are receiving inhaled therapies. It highlights the importance of effective management strategies to enhance patient care. The focus is on optimizing treatment approaches to mitigate cough symptoms associated with PAH.
Price reaction · baseline $0.7126 (2024-12-11 close) · hit after-hours · 1 other GOSS headline(s) in the window, move may be shared
day 0 close
+27.7%
day 1 · peak
+30.5%
day 3
+22.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Focus on best practices for managing cough in PAH patients.
  • Emphasis on inhaled therapies which may improve patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Best practices for managing cough in PAH patients receiving inhaled therapies
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the focus of the article?

The article focuses on best practices for managing cough in PAH patients receiving inhaled therapies.

Why is cough management important for PAH patients?

Effective cough management is crucial for enhancing the quality of life in PAH patients.

What therapies are discussed in relation to cough management?

The article discusses inhaled therapies as a key approach for managing cough in PAH patients.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare PAH cough management inhaled therapies Seralutinib PH-ILD
Last updated: Dec 11, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →